Leica Biosystems

Leica Biosystems (established in 1989) is a medical device firm that develops and sells clinical diagnostics to pathology labs. It is also a Danaher Corporation division and a research, instrument, and medical device company. It is the world's leading provider of workflow solutions, with the most comprehensive portfolio ranging from biopsy through diagnosis. From specimen preparation and staining through imaging and reporting, the company offers a comprehensive product line for every stage of the pathology process.

Leica Biosystems enables healthcare practitioners to provide correct diagnoses swiftly and consistently, translating concern into solutions for millions of patients worldwide. Its innovation is propelled by R&D investment, guided by customer feedback, and supported by a substantial patent portfolio. The organization is working hard to achieve the goal of enabling clinicians to rapidly offer patients with a very reliable diagnosis within 24-hours of biopsy.

Leica Biosystems is ideally positioned to break down the boundaries between each phase since it is the only business that owns the whole workflow from biopsy to diagnosis. The company's goal is to make diagnosis achievable within 24 hours after a biopsy. According to US News & World Report, 100 percent of the top 50 cancer facilities in the United States trust Leica Biosystems. Recent advances have concentrated on digital pathology with the introduction of the Aperio VERSA and LV1 scanners and histology equipment, including a next-generation H&E stainer.

Founded: 1989
Headquarters: Wetzlar, Germany
Website: https://www.leicabiosystems.com/